CAMBRIDGE, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic ...
The biotechnology firm Prime Medicine is approaching what could be its most definitive period. Following its 2025 annual results, the company is shifting its strategic emphasis from initial clinical ...
Prime editing is a powerful genome-editing technology that can achieve any possible base substitution, insertion, or deletion without the requirement for double strand breaks. However, challenges ...
Prime Medicine, Inc. (NASDAQ:PRME) is among the 12 Best Genomics Stocks to Invest In. Prime Medicine, Inc. (NASDAQ:PRME) stated on December 7, 2025, that the New England Journal of Medicine has ...
The U.S. Food and Drug Administration approved the first cell-based gene therapies for sickle cell disease, including the first-ever treatment built on CRISPR/Cas9 technology. That decision moved gene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results